HomeBUSINESS
BUSINESS

Oncologist Lauds Imfinzi as Trailblazer in Stage III Lung Cancer, Eagerly Awaiting OS Data
(Jul.24.2018)

Prof. Kazuhiko Nakagawa, Department of Medical Oncology, Kinki University Faculty of Medicine
The debut of AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will bring a bigger impact to the Stage III lung cancer space than what leading PD-1 products have done for Stage IV cancer, Prof. Kazuhiko Nakagawa, an oncologist at Kinki University, believes ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar